[go: up one dir, main page]

CO5261613A1 - INHIBITORS OF PHOSPHODIESTERASA-4 8-SUBSTITUTED ARILQUINOLINES - Google Patents

INHIBITORS OF PHOSPHODIESTERASA-4 8-SUBSTITUTED ARILQUINOLINES

Info

Publication number
CO5261613A1
CO5261613A1 CO00096650A CO00096650A CO5261613A1 CO 5261613 A1 CO5261613 A1 CO 5261613A1 CO 00096650 A CO00096650 A CO 00096650A CO 00096650 A CO00096650 A CO 00096650A CO 5261613 A1 CO5261613 A1 CO 5261613A1
Authority
CO
Colombia
Prior art keywords
alkyl
group
son
aryl
heteroaryl
Prior art date
Application number
CO00096650A
Other languages
Spanish (es)
Inventor
Denis Deschenes
Daniel Dube
Michael Gallant
Girard Yves
Patrick Lacombe
Macdonald Dwight
Anthony Mastracchio
Helene Perrier
Original Assignee
Merck Frosst Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Inc filed Critical Merck Frosst Canada Inc
Publication of CO5261613A1 publication Critical patent/CO5261613A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto representado por la Fórmula (I): <EMI FILE="00096650_1" ID="1" IMF=JPEG >ó una sal farmacéuticamente aceptable de éste, en donde: S1, S2, y S3 son independientemente H, -OH, halógeno, -alquil C1-C6, -NO2, -CN, ó -alcoxi C1-C6, en donde los grupos alquil y alcoxi van opcionalmente sustituidos con 1-5 sustituyentes; en donde cada sustituyente es independientemente un halógeno ó un OH; R1 es H, OH, halógeno, ó un grupo carbonilo, grupo -alquil C1-C6 grupo -cicloalquil C3-C6, grupo -alquenil C1-C6 grupo -alcoxi C1-C6, grupo aril, grupo heteroaril, -CN, grupo -heterociclo-alquil C1-C6, grupo -amino, grupo -alquilamino C1-C6, grupo -(alquil C1-C6)(alquil C1-C6)amino, grupo -alquil C1-C6-(oxi)-alquil C1-C6, grupo -C(O)NH(aril), grupo -C(O)NH(heteroaril), grupo -SOnNH(aril), grupo -SOnNH(heteroaril), grupo -SOnNH(alquil C1-C6), grupo -C(O)N(alquil C0-C6)(alquil C0-C6), grupo -NH-SOn-(alquil C1-C6), grupo -SOn-(alquil C1-C6), grupo -(alquil C1-C6)-O-C(CN)-dialquilamino, ó un grupo -(alquil C1-C6)-SOn-(alquil C1-C6), grupos cada uno de los cuales va opcionalmente sustituido con 1-5 sustituyentes; en donde cada sustituyente es independiente halógeno -OH, -CN, alquil C1-C6, cicloalquil C3-C6, -C(O)(heterociclo-alquil C3-C6), -C(O)-O-(alquil C0-C6), -C(O)-ariloxi, -alcoxi C1-C6, (alquil C0-C6)(alquil C0-C6)amino, cicloalquiloxi, acil, aciloxi, -cicloalquil C3-C6, heterocicloalquil C3-C6, aril, heteroaril, carbonil, carbamoil, ó -SOn-(alquil C1-C6); A es CH, C-éster, ó C-R4;R2 y R3 independientemente son aril, heteroaril, H, halógeno, -CN, -alquil C1-C6, -heterocicloalquil C3-C6, -alcoxi C1-C6 un grupo carbonilo, carbamoil, -C(O)OH, -(alquil C1-C6)-SOn-(alquil C1-C6), -C(O)N(alquil C0-C6)(alquil C0-C6), ó un grupo -alquilamino C1-C6 grupos los cuales van opcionalmente sustituidos con 1-5 sustituyentes, en donde cada sustituyente es independientemente halógeno, -NO2, -C(O)OH, -CN, N-óxido, -OH, ó un grupo sustituyente aril, heteroaril, carbonil, -alquil C1-C6, -SOn-(alquil C1-C6), -SOn-(aril), ariloxi, -heteroariloxi, alcoxi C1-C6, -C(O)-heterocicloalquil C3-C6, ...A compound represented by Formula (I): <EMI FILE = "00096650_1" ID = "1" MFI = JPEG> or a pharmaceutically acceptable salt thereof, wherein: S1, S2, and S3 are independently H, -OH, halogen, -C1-C6 alkyl, -NO2, -CN, or -C1-C6 alkoxy, wherein the alkyl and alkoxy groups are optionally substituted with 1-5 substituents; wherein each substituent is independently a halogen or an OH; R1 is H, OH, halogen, or a carbonyl group, -C1-C6 alkyl group, C3-C6 alkylcyclo group, C1-C6 alkenyl group, C1-C6 alkoxy group, aryl group, heteroaryl group, -CN, group - C1-C6 heterocyclo-alkyl, -amino group, C1-C6 -alkylamino group, group- (C1-C6 alkyl) (C1-C6 alkyl) amino, C1-C6 alkyl- (oxy) -C1-C6 alkyl group, group -C (O) NH (aryl), group -C (O) NH (heteroaryl), group -SOnNH (aryl), group -SOnNH (heteroaryl), group -SOnNH (C1-C6 alkyl), group -C ( O) N (C0-C6 alkyl) (C0-C6 alkyl), group -NH-SOn- (C1-C6 alkyl), group -SOn- (C1-C6 alkyl), group - (C1-C6 alkyl) -OC (CN) -dialkylamino, or a group - (C1-C6 alkyl) -SOn- (C1-C6 alkyl), groups each of which is optionally substituted with 1-5 substituents; wherein each substituent is independently halogen -OH, -CN, C1-C6 alkyl, C3-C6 cycloalkyl, -C (O) (heterocycle-C3-C6 alkyl), -C (O) -O- (C0-C6 alkyl ), -C (O) -aryloxy, -C1-C6 alkoxy, (C0-C6 alkyl) (C0-C6 alkyl) amino, cycloalkyloxy, acyl, acyloxy, -C3-C6 -cycloalkyl, C3-C6 heterocycloalkyl, aryl, heteroaryl , carbonyl, carbamoyl, or -SOn- (C1-C6 alkyl); A is CH, C-ester, or C-R4; R2 and R3 independently are aryl, heteroaryl, H, halogen, -CN, -C1-C6 alkyl, -C3-C6 heterocycloalkyl, a C1-C6 alkoxy a carbonyl group, carbamoyl, -C (O) OH, - (C1-C6 alkyl) -SOn- (C1-C6 alkyl), -C (O) N (C0-C6 alkyl) (C0-C6 alkyl), or a -alkylamino group C1-C6 groups which are optionally substituted with 1-5 substituents, wherein each substituent is independently halogen, -NO2, -C (O) OH, -CN, N-oxide, -OH, or an aryl, heteroaryl substituent group , carbonyl, -C1-C6 alkyl, -SOn- (C1-C6 alkyl), -SOn- (aryl), aryloxy, -heteroaryloxy, C1-C6 alkoxy, -C (O) -heterocycloalkyl C3-C6, ...

CO00096650A 1999-12-22 2000-12-20 INHIBITORS OF PHOSPHODIESTERASA-4 8-SUBSTITUTED ARILQUINOLINES CO5261613A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17152299P 1999-12-22 1999-12-22

Publications (1)

Publication Number Publication Date
CO5261613A1 true CO5261613A1 (en) 2003-03-31

Family

ID=22624050

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00096650A CO5261613A1 (en) 1999-12-22 2000-12-20 INHIBITORS OF PHOSPHODIESTERASA-4 8-SUBSTITUTED ARILQUINOLINES

Country Status (31)

Country Link
EP (1) EP1244628A1 (en)
JP (1) JP3782011B2 (en)
KR (1) KR20020082839A (en)
CN (1) CN1221534C (en)
AR (1) AR029214A1 (en)
AU (1) AU778531B2 (en)
BG (1) BG65403B1 (en)
BR (1) BR0016651A (en)
CA (1) CA2393749C (en)
CO (1) CO5261613A1 (en)
CZ (1) CZ20022171A3 (en)
DZ (1) DZ3244A1 (en)
EA (1) EA004747B1 (en)
EE (1) EE200200342A (en)
GE (1) GEP20053626B (en)
HR (1) HRP20020545A2 (en)
HU (1) HUP0203896A3 (en)
IL (1) IL150114A0 (en)
IS (1) IS6413A (en)
MX (1) MXPA02006329A (en)
MY (1) MY134008A (en)
NO (1) NO20023013L (en)
NZ (1) NZ520258A (en)
PE (1) PE20010989A1 (en)
PL (1) PL355752A1 (en)
SK (1) SK8972002A3 (en)
TW (1) TWI280240B (en)
UA (1) UA74815C2 (en)
WO (1) WO2001046151A1 (en)
YU (1) YU47102A (en)
ZA (1) ZA200204862B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776315B2 (en) 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
DE10110772A1 (en) * 2001-03-07 2002-09-12 Boehringer Ingelheim Pharma New drug compositions based on anticholinergics and PDE-IV inhibitors
ES2242787T3 (en) 2000-12-20 2005-11-16 MERCK &amp; CO., INC. PROCEDURE TO PREPARE SUBSTITUTED 8-ARILQUINOLINIO BENCENOSULPHONATES.
US6740666B2 (en) * 2000-12-20 2004-05-25 Merck & Co., Inc. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
ES2242036T3 (en) * 2001-06-27 2005-11-01 MERCK FROSST CANADA &amp; CO. 8-REPLACED ARILQUINOLINE PDE4 INHIBITORS.
WO2003010137A1 (en) * 2001-07-24 2003-02-06 Merck & Co., Inc. Preparation of sulfonyl quinoline
US20050014762A1 (en) * 2001-09-19 2005-01-20 Rolf Beume Combination
AU2003209896A1 (en) * 2002-03-18 2003-09-29 Merck Frosst Canada And Co. Hetero-bridge substituted 8-arylquinoline pde4 inhibitors
MXPA05009434A (en) * 2003-03-05 2005-11-23 Celgene Corp Diphenylethylene compounds and uses thereof.
CA2560895A1 (en) * 2004-03-25 2005-10-06 Synta Pharmaceuticals Corp. Acrylonitrile derivatives for inflammation and immune-related uses
AU2006248200A1 (en) * 2005-05-19 2006-11-23 Synergenz Bioscience Limited Methods and compositions for assessment of pulmonary function and disorders
RS53084B (en) 2006-07-05 2014-06-30 Takeda Gmbh COMBINATION OF HMG-COA ROSUVASTATIN REDUCTASE INHIBITOR WITH PHOSPHODIESTERASE 4 INHIBITOR, WHICH IS ROFLUMILAST, ROFLUMILAST-N-OXIDE FOR THE TREATMENT OF INFLAMMATORY LUNG DISEASES
MX2009000148A (en) * 2006-07-07 2009-10-26 Kalypsys Inc Bicyclic heteroaryl inhibitors of pde4.
AU2007299726A1 (en) * 2006-09-22 2008-03-27 Braincells, Inc. Combination comprising an HMG-COA reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
EP2291181B9 (en) 2008-04-18 2013-09-11 University College Dublin National University Of Ireland, Dublin Captodiamine for the treatment of depression symptoms
WO2011099305A1 (en) 2010-02-12 2011-08-18 Raqualia Pharma Inc. 5-ht4 receptor agonists for the treatment of dementia
EP2741777B1 (en) 2011-08-12 2017-01-18 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for treatment of pulmonary hypertension
WO2013054153A1 (en) 2011-10-11 2013-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Nutlin compounds for use in he treatment of pulmonary hypertension
EP3676262A4 (en) 2017-09-03 2021-03-31 Angion Biomedica Corp. Vinylheterocycles as rho-associated coiled-coil kinase (rock) inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9226830D0 (en) * 1992-12-23 1993-02-17 Celltech Ltd Chemical compounds
US5455252A (en) * 1993-03-31 1995-10-03 Syntex (U.S.A.) Inc. Optionally substituted 6,8-quinolines
US6245774B1 (en) * 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
JPH11209350A (en) * 1998-01-26 1999-08-03 Eisai Co Ltd Nitrogen-containing heterocyclic derivative and medicine containing the same

Also Published As

Publication number Publication date
BR0016651A (en) 2002-09-10
IS6413A (en) 2002-06-11
KR20020082839A (en) 2002-10-31
HRP20020545A2 (en) 2005-10-31
DZ3244A1 (en) 2001-06-28
SK8972002A3 (en) 2002-11-06
JP3782011B2 (en) 2006-06-07
WO2001046151A1 (en) 2001-06-28
MXPA02006329A (en) 2004-05-14
GEP20053626B (en) 2005-10-10
AU778531B2 (en) 2004-12-09
CN1221534C (en) 2005-10-05
HUP0203896A2 (en) 2003-04-28
EA004747B1 (en) 2004-08-26
NZ520258A (en) 2004-05-28
HUP0203896A3 (en) 2003-05-28
NO20023013L (en) 2002-08-22
CA2393749C (en) 2008-06-17
PL355752A1 (en) 2004-05-17
EA200200702A1 (en) 2003-02-27
TWI280240B (en) 2007-05-01
EE200200342A (en) 2003-06-16
IL150114A0 (en) 2002-12-01
AU2336201A (en) 2001-07-03
AR029214A1 (en) 2003-06-18
BG106840A (en) 2003-01-31
CA2393749A1 (en) 2001-06-28
BG65403B1 (en) 2008-06-30
YU47102A (en) 2005-06-10
CN1434801A (en) 2003-08-06
PE20010989A1 (en) 2001-10-01
NO20023013D0 (en) 2002-06-21
CZ20022171A3 (en) 2002-11-13
EP1244628A1 (en) 2002-10-02
ZA200204862B (en) 2003-03-17
MY134008A (en) 2007-11-30
JP2003531112A (en) 2003-10-21
HK1057560A1 (en) 2004-04-08
UA74815C2 (en) 2006-02-15

Similar Documents

Publication Publication Date Title
CO5261613A1 (en) INHIBITORS OF PHOSPHODIESTERASA-4 8-SUBSTITUTED ARILQUINOLINES
AU2002360797A8 (en) Acridone inhibitors of impdh enzyme
CO5261497A1 (en) RANGE-HYDROXI-2- (FLUOROALQUILAMINO-CARBONIL) -1-PIPERAZINO PENTANAMIDAS AND ITS USES
AR044749A1 (en) INHIBITOR OF THE RNA DEPENDENT RNA POLYMERASE OF THE HEPATITIS C VIRUS AND COMPOSITIONS AND TREATMENTS USING
CO4910135A1 (en) CETOLID DERIVATIVES 6-0 SUBSTITUTED FOR ERYTHROMYCIN THAT HAVE BACTERIAL ACTIVITY
CO5080782A1 (en) HETEROCICLICAL COMPOUNDS AS INHIBITORS OF ROTAMASA ENZYMES
RU2004137480A (en) Hepatitis C Virus Inhibitors
TW359670B (en) Process for producing quinazolin-4-one derivatives
CO5251410A1 (en) NITRILE DERIVATIVES AS INHIBITORS OF CAPTESIN K
CA2615022A1 (en) Hcv ns3 protease inhibitors
TW200510338A (en) 3-substituted-4-pyrimidone derivatives
EA200300763A1 (en) PYRIDINE INHIBITORS OF MATRIX METALLOPROTEINASES
CO5170518A1 (en) N- (BENZOCICLOALQUILO) COMPOUNDS DERIVED FROM AMINO ARALIFATICOS
CO5261616A1 (en) NON-PEPTIDIC INHIBITORS OF THE CELLULAR UNION DEPENDENTS OF VLA-4 USEFUL IN THE TREATMENT OF INFLAMMATORY, AUTOIMMUNE AND RESPIRATORY DISEASES
TW200640885A (en) Novel haoalkanesulfonylaniline derivatives, weed killer and the use methods thereof
RU93005332A (en) DERIVATIVES 4,1-BENZOXAZEPINA, PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT
CO5130004A1 (en) 1-ARIL-3-ARILMETIL-1,8-NAFTIRIDIN-4 (1H) -ONAS
WO2000009483A3 (en) Process and intermediates for production of donepezil and related compounds
CO4900066A1 (en) TETRAHYDROKINOLINE DERIVATIVES
ATE171188T1 (en) 4-AZASTEROIDS SUBSTITUTED IN THE 15 POSITION
RU2007132260A (en) SYNTHESIS OF ARILPYRROLIDONES
EP1465488A4 (en) Arylamines as inhibitors of chemokine binding to us28
CO5140112A1 (en) BENZIMIDAZOL COMPOUNDS THAT ARE VITRONECTINE RECEPTOR ANTAGONISTS
CO5170520A1 (en) DERIVATIVES OF 4- (REPLACED PHENYL) -2-PIPERAZINIL-PIRIMIDIN- (3,5-BISTRIFLUORO-METIL-BENCIL) - METIL-AMIDA
TW200512181A (en) Amide-type carboxamide derivatives

Legal Events

Date Code Title Description
FC Application refused